[New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
Despite widely accepted efficacy of bisphophonates for osteoporotic fracture, patients treatment compliance has been low, especially, with daily regimen, in part because of the inconvenience associated with special dosing requirements of oral bisphophonates. Intermittent bisphophonates, oral and intravenous, have been introduced to solve the problem. In Japan, at present, only weekly alendronate and risedronate, both oral, have been approved for osteoporosis. In U. S. A. and other countries, orally, monthly risedoronate and ibandronate, intravenously, quarterly ibandronate and yearly zoledronate have been approved for osteoporosis. Their clinical efficacy will be reviewed.
Okazaki
Ryo
R
Teikyo University Chiba Medical Center, Third Department of Medicine, Japan.
D019386:Alendronate / Q000008:administration & dosage; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives; D005598:Fractures, Spontaneous / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D000077557:Ibandronic Acid; D007093:Imidazoles / Q000008:administration & dosage; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy*; D010349:Patient Compliance; D000068296:Risedronic Acid; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D000068296:Risedronic Acid; D012968:Etidronic Acid; D000077557:Ibandronic Acid; D019386:Alendronate